How to read this overview
Telehealth prescribing is governed by a patchwork: federal law, the medical and pharmacy boards of all fifty states, and — for certain drugs — the DEA. There is no single national rulebook, and the details differ from state to state and change regularly. Anyone who hands you a tidy "here are the rules in all 50 states" table is selling you a snapshot that starts going stale the day it's printed.
So this guide is deliberately an overview of the framework, not a 50-state directory. The goal is to give you, as a clinic operator, the mental model to understand what questions matter, why coverage across states is hard, and where you need to lean on your providers and legal counsel. The specific requirements for any given state and any given medication must be confirmed with people qualified to give that advice for your situation — this is orientation, not legal advice.
Three threads run through almost every state's rules: how a provider establishes a legitimate relationship with a patient, what kind of examination is required before prescribing, and the special handling of controlled substances. Understand those three and you understand most of the terrain.
Establishing a legitimate provider-patient relationship
The foundation of any prescription — in person or via telehealth — is a valid provider-patient relationship. A provider generally cannot lawfully prescribe to someone who is not, in a meaningful clinical sense, their patient. The core question every state asks is: did a real clinical relationship exist, supported by an appropriate evaluation, before the prescription was written?
Where states differ is in how that relationship can be established at a distance. Many states now accept that a provider-patient relationship can be created through telehealth without a prior in-person visit, provided the evaluation is adequate for the clinical situation. Others impose additional conditions, and some treat certain drug categories or certain first encounters differently. The common thread is that the relationship has to be genuine: enough clinical information, gathered through an appropriate process, for the provider to make a sound decision. A questionnaire that rubber-stamps a predetermined prescription is the model regulators scrutinize hardest.
For an operator, the design implication is the same one that runs through good telehealth generally: build the workflow so a real evaluation precedes the prescription, and so the record shows it. The provider's judgment about whether a valid relationship and adequate evaluation exist is the load-bearing element — not the marketing funnel that brought the patient in.
Async vs synchronous: what kind of exam is required
A central variable in state rules is what form of interaction counts as an adequate examination. The terms are worth getting straight, because they shape which programs are viable in which states.
A live interaction — video or, in some cases, audio — between provider and patient. It most closely mirrors an in-person visit and is the most broadly accepted form across states.
The patient submits information (intake, photos, history) the provider reviews later. Some states permit async for certain situations; others require a synchronous or in-person component first.
Real-time voice without video. Some states and payers treat it differently from full video, and acceptability can depend on clinical context and drug category.
States weigh access against the risk a limited exam misses something. The same async program may be fine in one state and require a live visit in another — and those lines move.
Controlled substances: the DEA layer on top
When a prescription is for a controlled substance, a whole additional layer of federal rules applies on top of state law. The central federal statute here is the Ryan Haight Act, which, broadly, requires at least one in-person medical evaluation before a controlled substance is prescribed via telemedicine — subject to specific exceptions. The DEA administers this framework.
During the COVID-19 public health emergency, the DEA and HHS granted temporary flexibilities that relaxed the in-person requirement for many controlled-substance telemedicine prescriptions. Those flexibilities have been repeatedly extended while the DEA works through permanent rulemaking, which means the exact requirements have been a moving target and remain subject to change. The direction of travel, the categories affected, and the effective dates are precisely the kind of detail that is unsafe to rely on from memory — this is an area to verify current status with counsel before building a controlled-substance workflow.
The practical operator takeaway: controlled substances are a materially higher-complexity category than non-controlled medications, and many turnkey telehealth programs deliberately focus on non-controlled therapies for exactly that reason. If your program contemplates controlled substances, treat the federal telemedicine and DEA requirements as a first-order design constraint, not an afterthought, and get qualified legal input on the current rules before you launch.
Nothing here is legal advice. Telehealth prescribing requirements vary by state and by medication, and both state rules and federal controlled-substance rules change over time. All prescribing and eligibility decisions rest with a licensed provider, and any program you design should be confirmed against current requirements by your providers and legal counsel before you rely on it.
Documentation and the standard of care
Underneath the state-by-state variation sits a principle that is remarkably consistent: telehealth prescribing is held to the same standard of care as in-person medicine. A provider is expected to gather enough information, exercise the same clinical judgment, and document the encounter as they would in a physical exam room. The medium changes; the professional obligation does not.
For an operator, that principle is clarifying, because it tells you what to build toward even when the specific rules differ. Whatever a given state requires — synchronous video, an async review, an in-person component for certain drugs — the workflow should capture a genuine evaluation and produce a record that demonstrates one occurred. Good documentation is not bureaucratic overhead; it is the evidence that the standard of care was met, and it is the first thing anyone reviewing a program will look for.
This is also why the provider's clinical judgment has to remain central rather than being engineered out of the flow. A program optimized purely for conversion — where the interface nudges every patient toward the same prescription and the provider's role shrinks to a signature — undermines both the standard of care and the record that proves it was met. Building the workflow so the provider genuinely evaluates and decides is not a constraint on the business; over time it is what protects it.
Why a 50-state provider network matters
Once you internalize that prescribing authority follows provider licensure and that each state has its own rules, the operational challenge becomes obvious. A provider can generally only treat patients in states where they are licensed. If you want to serve patients across the country, you either need providers licensed in each of those states or a network that already has that coverage.
Building multi-state licensure yourself is slow and expensive — it means recruiting, credentialing, and maintaining licensure for providers across many jurisdictions, then keeping up with each state's evolving telehealth and prescribing rules. This is where a 50-state provider network changes the math. Instead of assembling coverage state by state, a clinic without prescribers in every state can use a network of board-certified providers who are already licensed across all fifty, with the clinical decision still resting fully with those providers.
That coverage is also what makes national marketing viable. There's little point driving demand from patients across the country if you can only lawfully serve a handful of states. A 50-state network lets a growing clinic accept patients wherever they are, while the network absorbs the licensure and much of the jurisdictional complexity. If you're weighing how to launch broadly, our white-label telehealth and TRT clinic pages show how multi-state coverage plugs into a real program.
Serve patients nationwide without building 50-state licensure
Heally bundles a 50-state provider network with software and pharmacy fulfillment, so you can launch broadly under your own brand — with no startup fees and setup typically in under a day.
Building a program that adapts as the rules move
The single most important design principle for telehealth prescribing is to assume the rules will change. Async-versus-synchronous expectations shift. Controlled-substance flexibilities get extended, narrowed, or made permanent. States revise how a provider-patient relationship may be established. A program hard-wired to today's rules becomes tomorrow's liability.
Practically, that means building on infrastructure that tracks and adapts to those changes rather than trying to freeze a compliant configuration in place. It means keeping the provider's clinical judgment central, so that whatever the exam requirements are in a given state, your workflow can satisfy them. And it means partnering with people whose job is to follow this terrain. Heally's model — software, a 50-state provider network, and pharmacy fulfillment bundled together — is built so that the licensure, workflow, and much of the compliance scaffolding move with the rules instead of against them.
The alternative — stitching together a separate software vendor, your own multi-state provider recruiting, and an independent pharmacy relationship — leaves you carrying the coordination and the regulatory-tracking burden across three moving systems that each change on their own schedule. That is exactly the fragility this guide is meant to help you avoid. Bundling those layers means that when a state revises its telehealth rules or the DEA updates its controlled-substance stance, the change is absorbed in one place rather than rippling unmanaged across vendors. If you're building a business from scratch, pair this with our guide on how to start a telehealth business, and let your providers and counsel confirm the specifics for your states and services.
Telehealth prescribing questions operators ask
Is there one national rule for telehealth prescribing?+
No. It's a patchwork of federal law, all fifty states' medical and pharmacy boards, and — for controlled substances — the DEA. Requirements differ by state and by medication and change over time, which is why this guide is a framework overview rather than a 50-state table. Confirm specifics with your providers and legal counsel.
Can a provider prescribe after an online-only visit?+
Often, yes, provided a legitimate provider-patient relationship and an adequate evaluation exist for the clinical situation — but the conditions vary by state, and some drug categories are treated differently. The provider's judgment about whether the evaluation is sufficient is the key element.
What's the difference between async and synchronous telehealth?+
Synchronous is a live, real-time interaction (typically video); asynchronous is store-and-forward, where the provider reviews submitted information later without a live conversation. States differ on when async is acceptable for prescribing, and some require a synchronous or in-person component.
Are controlled substances harder to prescribe via telehealth?+
Yes. Federal law — notably the Ryan Haight Act, administered by the DEA — adds requirements on top of state rules, generally centered on in-person evaluation with specific exceptions. Pandemic-era flexibilities have been extended and remain subject to change, so confirm current rules with counsel before building a controlled-substance workflow.
Why does a 50-state provider network matter?+
Because prescribing authority follows provider licensure. To serve patients nationwide you need providers licensed in each state or a network that already has that coverage. A 50-state network lets a clinic without prescribers everywhere serve patients across all fifty, with clinical decisions resting with the providers.
Do we need our own providers to use Heally?+
No. If you have your own providers, coverage follows their licensure. If you don't — or you lack coverage in some states — you can use Heally's 50-state network of board-certified providers, so you can launch broadly without building multi-state licensure yourself. See <a href="/programs/add-glp-1">adding a GLP-1 program</a> for an example.
How do we keep a program compliant as rules change?+
Build on infrastructure that tracks and adapts to regulatory changes, keep the provider's clinical judgment central to every prescription, and confirm requirements with legal counsel for the states and services you offer. Assume the rules will move and design so your workflow can move with them.
Keep exploring
Schedule a demo
See how quickly you can run your whole clinic on Heally — software, a 50-state provider network, and pharmacy fulfillment, handled from day one.